FCGR2A and neoplasm: Several in vitro and in vivo studies have shown that this chimeric IgG1 mAb binds to the antigen, the EGFR, on the surface of tumor cells while its Fc portion binds to the immune effector cells through FCγ R. Consequently, this binding activates the immune cells leading to tumor cells killing.